Fundraising Fox
Olatec Therapeutics
New York, US · 2 known investors
Find your way into Olatec Therapeutics
Sign up to see every warm intro you have to Olatec Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Olatec Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.
Founders & leadership
Investors · 2
Also in the syndicate · 1
Sanders Morris Harrislead
Funding
SEC filings, press & company announcements- Undisclosed amountSeries AFeb 2023
Sanders Morris Harris (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Olatec Therapeutics do?
- Olatec develops a pharmaceutical platform targeting acute and chronic inflammatory diseases, with its lead compound dapansutrile (OLT1177), a NLRP3 inhibitor currently in Phase 2 clinical trials in the US and Europe.
- Who founded Olatec Therapeutics?
- Olatec Therapeutics was founded by Damaris Skouras.
- Who are Olatec Therapeutics's investors?
- Olatec Therapeutics's investors include Advection Growth Capital.
- Where is Olatec Therapeutics headquartered?
- Olatec Therapeutics is headquartered in New York, US.